Holen Sie sich die Stockscreener-App
9.75
2.89%
-0.29
Handel nachbörslich:
9.40
-0.35
-3.59%
Schlusskurs vom Vortag:
$10.04
Offen:
$10.06
24-Stunden-Volumen:
3.96M
Relative Volume:
1.77
Marktkapitalisierung:
$1.02B
Einnahmen:
$69.65M
Nettoeinkommen (Verlust:
$-81.27M
KGV:
-10.73
EPS:
-0.9088
Netto-Cashflow:
$-79.45M
1W Leistung:
-12.48%
1M Leistung:
+63.04%
6M Leistung:
+5.29%
1J Leistung:
+80.56%
1-Tages-Spanne:
$9.08
$10.12
1-Wochen-Bereich:
$9.08
$12.53
52-Wochen-Spanne:
$3.84
$12.53
Personalis Inc Stock (PSNL) Company Profile
Firmenname
Personalis Inc
Sektor
Branche
Telefon
650-752-1300
Adresse
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
9.75 | 1.05B | 69.65M | -81.27M | -79.45M | -0.9088 |
TMO
Thermo Fisher Scientific Inc
|
494.07 | 174.52B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
188.41 | 129.90B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
578.89 | 44.27B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.48 | 37.48B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
371.15 | 35.67B | 3.77B | 449.25M | 240.68M | 7.8556 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-15 | Eingeleitet | Guggenheim | Buy |
| 2025-03-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-06 | Hochstufung | Needham | Hold → Buy |
| 2022-01-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Herabstufung | Needham | Buy → Hold |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-20 | Bestätigt | Needham | Buy |
| 2021-05-06 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-12 | Bestätigt | Needham | Buy |
| 2020-11-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-07-15 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Personalis Inc Aktie (PSNL) Neueste Nachrichten
Personalis blood collection kits receive EU regulatory approval - Investing.com UK
Personalis (PSNL) Receives CE Mark Approval for Blood Collection Kits - GuruFocus
Personalis blood collection kits receive EU regulatory approval By Investing.com - Investing.com South Africa
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits - Business Wire
Personalis, Inc. Hits Day Low of $10.39 Amid Price Pressure - MarketsMojo
Personalis, Inc. Hits New 52-Week High of $11.84, Up 763.64% - MarketsMojo
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
Personalis CFO Aaron Tachibana sells $480,400 in company stock - Investing.com UK
Personalis CFO Aaron Tachibana sells $480,400 in company stock By Investing.com - Investing.com Nigeria
Personalis (NASDAQ: PSNL) CFO sells 40,000 shares under 10b5-1 plan - Stock Titan
Aaron L. Tachibana (PSNL) exercises 40,000 options; prior 38,799 10b5-1 sale - Stock Titan
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors? - The Globe and Mail
Personalis Data Highlights Early Cancer Recurrence Detection - Clinical Lab Products
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026 - BioSpace
Assessing Personalis (PSNL) Valuation After Its Strong Recent Share Price Momentum - Yahoo Finance
Personalis Insider Sold Shares Worth $449,292, According to a Recent SEC Filing - marketscreener.com
Personalis CFO and COO Aaron Tachibana sells $449,292 in stock By Investing.com - Investing.com India
Personalis CEO Christopher M. Hall sells $1.1m in stock By Investing.com - Investing.com India
Personalis CEO Christopher M. Hall sells $1.1m in stock - Investing.com
Personalis CFO and COO Aaron Tachibana sells $449,292 in stock - Investing.com
Personalis (NASDAQ: PSNL) CEO sells 100K shares after exercising options - Stock Titan
Personalis (PSNL) CFO sells shares via pre-set Rule 10b5-1 plan - Stock Titan
Personalis (PSNL) Is Up 34.5% After CMS Expands NeXT Personal MRD Test Medicare Coverage - simplywall.st
Personalis stock hits 52-week high at $11.51 By Investing.com - Investing.com Australia
[144] Personalis, Inc. SEC Filing - Stock Titan
Personalis, Inc. Hits Day High with 15.7% Surge in Stock Price - MarketsMojo
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating (NASDAQ:PSNL) - Seeking Alpha
ETFs Investing in Personalis, Inc. Stocks - TradingView
Personalis gains after fourth Medicare coverage win for NeXT Personal - MSN
Medicare to Cover Personalis’ NeXT Personal Assay for Immunotherapy Monitoring in Late-Stage Solid Tumor Patients - geneonline.com
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium - BioSpace
Personalis Inc. (PSNL) Rallies 2.67% as Volume Picks Up – Key Levels in SightFair Value Gap - thelegaladvocate.com
Personalis Inc. (PSNL) Surges 4.5% as Stock Tests Key Resistance Near $9.05Overnight Profile - thelegaladvocate.com
Craig-Hallum Maintains Personalis(PSNL.US) With Buy Rating - Moomoo
Personalis outlines 2026 clinical volume target of 43,000 to 45,000 tests while reaffirming $78M to $80M revenue guidance - MSN
Personalis NeXT Disease Test Approved for Expanded Coverage by Medicare, Medicaid - Moomoo
Lake Street Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Medicare Expands Coverage for Personalis NeXT Personal Test - TipRanks
US agency broadens coverage of Personalis breast cancer test - MSN
Expanded Medicare covers Personalis (NASDAQ: PSNL) NeXT Personal cancer test - Stock Titan
Personalis gains expanded Medicare coverage for breast cancer test By Investing.com - Investing.com Nigeria
Finanzdaten der Personalis Inc-Aktie (PSNL)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):